Nuveen LLC Takes $2.29 Million Position in OPKO Health, Inc. $OPK

Key Points

• Nuveen LLC has acquired a new stake in OPKO Health, purchasing 1,376,881 shares valued at approximately $2.29 million, thereby holding 0.17% of the company.
• CEO Phillip Frost purchased 675,000 shares at $1.32 each, increasing his ownership by 0.32% to a total of 214,676,448 shares valued at around $283 million.
• OPKO Health reported a loss of $0.19 per share for the last quarter, missing analysts' expectations and showing a revenue drop of 13.9% year-over-year.

Nuveen LLC purchased a new stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,376,881 shares of the biotechnology company's stock, valued at approximately $2,286,000. Nuveen LLC owned 0.17% of OPKO Health at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OPK. Wells Fargo & Company MN lifted its holdings in shares of OPKO Health by 14.9% during the fourth quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock valued at $337,000 after acquiring an additional 29,738 shares during the period. Raymond James Financial Inc. bought a new stake in shares of OPKO Health during the fourth quarter worth $221,000. Barclays PLC grew its holdings in shares of OPKO Health by 68.7% during the fourth quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after purchasing an additional 373,032 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of OPKO Health by 40.8% during the fourth quarter. MetLife Investment Management LLC now owns 202,165 shares of the biotechnology company's stock worth $297,000 after purchasing an additional 58,589 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of OPKO Health by 4.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company's stock worth $670,000 after purchasing an additional 18,571 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 675,000 shares of the business's stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the transaction, the chief executive officer owned 214,676,448 shares in the company, valued at $283,372,911.36. The trade was a 0.32% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 49.69% of the company's stock.

OPKO Health Stock Performance

NASDAQ OPK traded down $0.04 on Monday, hitting $1.38. 1,663,914 shares of the stock were exchanged, compared to its average volume of 2,347,663. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The business's fifty day moving average is $1.34 and its 200 day moving average is $1.45. OPKO Health, Inc. has a 52 week low of $1.11 and a 52 week high of $2.04. The company has a market capitalization of $1.10 billion, a PE ratio of -5.52 and a beta of 1.40.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The company's revenue for the quarter was down 13.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.01) earnings per share. Research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on OPK shares. Zacks Research upgraded OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Wall Street Zen lowered OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Finally, LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.